"SomnoMed has received approval to begin the commercialisation of the world’s first oral device for Obstructive Sleep Apnea (OSA) with the ability to objectively measure compliance rates and report back to the clinicians. This is a very important step for the efficacy of COAT ™ devices to clinicians/insurers and we believe this ability will act as a door opener to the prescribers and payers alike for mild to moderate sleep apnea. We upgrade our price target to A$3.23 and retain an Add recommendation. "
Morgans blog video update: http://www.morgans.com.au/Blog/2015/June/Healthcare-update-23-June-2015.aspx
Morgans increases price target to $3.23
Add SOM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.010(2.78%) |
Mkt cap ! $77.79M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 35.0¢ | 35.0¢ | $3.01K | 8.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 14911 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 1254 | 1 |
View Market Depth
| Last trade - 11.46am 10/07/2024 (20 minute delay) ? |
| SOM (ASX) Chart |